Neurocrine Biosciences (NBIX) Competitors $109.68 +3.09 (+2.90%) Closing price 04:00 PM EasternExtended Trading$109.15 -0.53 (-0.48%) As of 04:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. ALNY, BIIB, UTHR, BMRN, INCY, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, dividends, valuation, earnings, profitability, community ranking and analyst recommendations. Is ALNY or NBIX more profitable? Neurocrine Biosciences has a net margin of 14.49% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Neurocrine Biosciences' return on equity of 13.38% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Neurocrine Biosciences 14.49%13.38%9.73% Do institutionals & insiders have more ownership in ALNY or NBIX? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor ALNY or NBIX? In the previous week, Alnylam Pharmaceuticals had 2 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 33 mentions for Alnylam Pharmaceuticals and 31 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.59 beat Alnylam Pharmaceuticals' score of 0.58 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 18 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Neurocrine Biosciences 13 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, ALNY or NBIX? Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Does the MarketBeat Community prefer ALNY or NBIX? Alnylam Pharmaceuticals received 128 more outperform votes than Neurocrine Biosciences when rated by MarketBeat users. However, 77.62% of users gave Neurocrine Biosciences an outperform vote while only 76.29% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes116576.29% Underperform Votes36223.71% Neurocrine BiosciencesOutperform Votes103777.62% Underperform Votes29922.38% Do analysts prefer ALNY or NBIX? Alnylam Pharmaceuticals presently has a consensus target price of $316.63, suggesting a potential upside of 22.21%. Neurocrine Biosciences has a consensus target price of $160.90, suggesting a potential upside of 46.63%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77Neurocrine Biosciences 0 Sell rating(s) 3 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.86 Which has stronger valuation and earnings, ALNY or NBIX? Neurocrine Biosciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B14.99-$278.16M-$2.17-119.39Neurocrine Biosciences$2.36B4.61$341.30M$3.2933.35 SummaryNeurocrine Biosciences beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.86B$2.96B$5.54B$8.06BDividend YieldN/A1.87%5.09%4.22%P/E Ratio33.3730.4322.7418.82Price / Sales4.61501.41406.04107.26Price / Cash34.35168.6838.1834.62Price / Book4.233.216.804.35Net Income$341.30M-$72.35M$3.22B$247.85M7 Day Performance2.82%4.12%2.24%2.83%1 Month Performance1.32%7.72%3.58%4.32%1 Year Performance-21.52%-22.14%16.74%5.96% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.8854 of 5 stars$109.68+2.9%$160.90+46.7%-25.5%$10.85B$2.36B33.341,200Upcoming EarningsALNYAlnylam Pharmaceuticals4.2256 of 5 stars$254.85+1.3%$315.58+23.8%+70.1%$33.15B$2.25B-117.442,000Earnings ReportAnalyst DowngradeNews CoverageBIIBBiogen4.7154 of 5 stars$119.12+0.2%$203.07+70.5%-44.0%$17.44B$9.68B10.658,720Earnings ReportAnalyst ForecastNews CoverageUTHRUnited Therapeutics4.9886 of 5 stars$297.04+1.9%$390.17+31.4%+15.2%$13.34B$2.88B13.05980Earnings ReportAnalyst ForecastInsider TradePositive NewsBMRNBioMarin Pharmaceutical4.9303 of 5 stars$62.98-0.5%$93.14+47.9%-24.7%$12.02B$2.85B28.633,080Analyst ForecastNews CoveragePositive NewsGap UpINCYIncyte4.7432 of 5 stars$59.52+0.6%$74.69+25.5%+17.2%$11.52B$4.24B220.452,320Earnings ReportAnalyst ForecastAnalyst RevisionEXELExelixis4.0986 of 5 stars$38.44+2.7%$37.59-2.2%+77.4%$10.59B$2.17B21.721,220Short Interest ↑Analyst RevisionPositive NewsEXASExact Sciences4.5181 of 5 stars$45.59+0.3%$69.25+51.9%-21.4%$8.47B$2.76B-8.186,400Earnings ReportAnalyst ForecastNews CoveragePositive NewsGap UpRGENRepligen4.6448 of 5 stars$143.63-0.8%$176.82+23.1%-13.4%$8.06B$634.44M-281.632,020Earnings ReportAnalyst UpgradeAnalyst RevisionNews CoveragePositive NewsHALOHalozyme Therapeutics4.0233 of 5 stars$60.57+0.1%$62.89+3.8%+52.7%$7.48B$1.02B17.66390Upcoming EarningsAnalyst RevisionMDGLMadrigal Pharmaceuticals4.6201 of 5 stars$331.29+1.4%$409.00+23.5%+55.6%$7.31B$180.13M-13.2190Earnings ReportAnalyst ForecastNews CoveragePositive News Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Incyte Competitors Exelixis Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NBIX Stock Free NBIX Stock Alerts